✦ LIBER ✦

Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma

✍ Scribed by Van Den Neste, E; Louviaux, I; Michaux, J L; Delannoy, A; Michaux, L; Sonet, A; Bosly, A; Doyen, C; Mineur, P; André, M

Book ID: 110054560
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 100 KB
Volume: 14
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2401783

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II study examining pentostatin

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma

✍ Carl R. Willis; Amy Goodrich; Kathy Park; Jamie K. Waselenko; Margaret Lucas; Am 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 114 KB

Phase I/II and pharmacokinetic study of

Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab

✍ Kensei Tobinai; Takashi Watanabe; Kazuki Tanimoto; Dai Maruyama; Masanobu Nakata 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

A phase II study of sequential combinati

A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia

✍ Tefferi, A; Li, C-Y; Reeder, C B; Geyer, S M; Allmer, C; Levitt, R; Michalak, J 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

Prolonged follow-up after initial therap

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma : Results of Cancer and Leukemia Group B Study 9153

✍ Kristie A. Blum; Jeffrey L. Johnson; Donna Niedzwiecki; Lawrence D. Piro; Alan S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 3 views

A randomized phase 2 study of PBPC mobil

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma

✍ Stiff, P; Gingrich, R; Luger, S; Wyres, M R; Brown, R A; LeMaistre, C F; Perry, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 122 KB

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552

✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and